Biospecifics Tech Cp (BSTC) 37.55 $BSTC AstraZeneca

New Post Public Reply Private Reply Replies (0) Message Board

Sep 2, 2016 at 3:13 AM

Biospecifics Tech Cp (BSTC) 37.55 $BSTC

AstraZeneca Asthma Drug Symbicort Positive in Safety Trial
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 9:21AM CDT
AstraZeneca PLC (AZN) announced positive results from a safety study on Symbicort inhaler in patients suffering from asthma compared to budesonide alone.
BSTC: 37.55 (+0.96), AZN: 32.60 (-0.21), OHRP: 2.77 (-0.09)

Dipexium Pharmaceuticals (DPRX) in Focus: Stock Gains 8.5%
Zacks Equity Research - Zacks Investment Research - Thu Sep 01, 7:45AM CDT
Dipexium Pharmaceuticals, Inc. (DPRX) was a big mover last session, as the company saw its shares rise over 8% on the day.
BSTC: 37.55 (+0.96), DPRX: 12.79 (+0.09)

What Makes Collegium Pharmaceutical (COLL) a Strong Sell?
Zacks Equity Research - Zacks Investment Research - Tue Aug 30, 7:25AM CDT
Collegium Pharmaceutical (COLL) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 37.55 (+0.96), COLL: 8.83 (+0.50)

The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 8:30AM CDT
The Zacks Analyst Blog Highlights: Mylan, Teva Pharmaceutical, Lannett Company, BioSpecifics Technologies and USANA Health Sciences
LCI: 33.37 (-0.49), BSTC: 37.55 (+0.96), MYL: 41.92 (-0.44), USNA: 136.35 (-0.39), TEVA: 50.90 (+0.51)

Weakness Seen in Jazz Pharmaceuticals (JAZZ) Estimates: Should You Stay Away?
Zacks Equity Research - Zacks Investment Research - Mon Aug 29, 7:32AM CDT
Jazz Pharmaceuticals (JAZZ) has witnessed a significant price decline and negative trend in earnings estimate revisions in the past four weeks
BSTC: 37.55 (+0.96), JAZZ: 123.31 (-0.52)

Forget Mylan, Buy These 3 Drug Stocks Instead
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 1:44PM CDT
With Mylan under pricing scrutiny, investors should focus on these top-ranked drug stocks now.
LCI: 33.37 (-0.49), ENDP: 20.23 (-0.47), VRX: 29.12 (+0.09), BSTC: 37.55 (+0.96), MYL: 41.92 (-0.44), TEVA: 50.90 (+0.51), USNA: 136.35 (-0.39)

New Strong Buy Stocks for August 22nd
Tirthankar Chakraborty - Zacks Investment Research - Mon Aug 22, 7:36AM CDT
New Strong Buy Stocks for August 22nd
BSTC: 37.55 (+0.96), DTLK: 9.98 (+0.24), SNP: 71.34 (-0.03), COTV: 32.53 (-0.71), AEIS: 45.00 (+1.05)

Catalyst Pharmaceuticals (CPRX) Looks Good: Stock Up 6.3%
Zacks Equity Research - Zacks Investment Research - Thu Aug 18, 7:45AM CDT
Catalyst Pharmaceuticals, Inc. (CPRX) was a big mover last session, as the company saw its shares rise over 6% on the day.
BSTC: 37.55 (+0.96), CPRX: 0.96 (-0.05)

BioSpecifics Technologies Corp. Reports Second Quarter 2016 Financial Results
PR Newswire - Tue Aug 09, 3:05PM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the second quarter ended June 30, 2016 and provided a corporate update.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. to Report Second Quarter 2016 Financial Results on Tuesday, August 9, 2016
PR Newswire - Tue Aug 02, 7:00AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, announced today that it will host a conference call and live audio webcast at 4:30 p.m. ET on Tuesday, August 9, 2016 to report its second quarter 2016 financial results and to provide a corporate update.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. Announces Positive Top-Line Results from Phase 2 Trial of CCH for Treatment of Human Lipoma
PR Newswire - Mon Jun 13, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC) today announced positive, statistically significant top-line results from a placebo-controlled, double-blind Phase II clinical trial of collagenase clostridium histolyticum (CCH) for the treatment of human lipoma. The trial met its primary endpoint of reduction in the visible surface area of the target lipomas relative to placebo, as determined by caliper, at six months post injection (p<0.0001), and also met all secondary efficacy endpoints. There were no serious adverse events reported during the trial.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. to Present at the Jefferies 2016 Healthcare Conference
PR Newswire - Thu Jun 02, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming Jefferies 2016 Healthcare Conference on Thursday, June 9, 2016 at 8:00 a.m. ET in New York, NY.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. Announces Publication of Encouraging Data for Uterine Fibroid Treatment with CCH in American Journal of Obstetrics & Gynecology
PR Newswire - Tue May 31, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced the publication of data highlighting the efficacy of collagenase clostridium histolyticum (CCH) for the treatment of uterine fibroids in the May 2016 issue of the American Journal of Obstetrics & Gynecology in an article titled, "Loss of Stiffness in Collagen-Rich Uterine Fibroids after Digestion with Purified Collagenase Clostridium Histolyticum." The data show that highly purified CCH can reduce the stiffness of human uterine fibroids ex-vivo and potentially decrease their size.
BSTC: 37.55 (+0.96)

BioSpecifics Technologies Corp. to Present at the 2016 UBS Global Healthcare Conference
PR Newswire - Wed May 18, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the upcoming 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016 at 3:00 p.m. ET in New York, NY.
BSTC: 37.55 (+0.96)

New Strong Sell Stocks for May 13th
Zacks Equity Research - Zacks Investment Research - Fri May 13, 9:48AM CDT
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List for Friday
AIXG: 6.16 (unch), BSTC: 37.55 (+0.96), AZZ: 66.62 (+0.19), ASB: 19.68 (-0.16), AHT: 6.76 (-0.21)

Repros (RPRX) Q1 Loss Narrower Y/Y, Pipeline in Focus
Arpita Dutt - Zacks Investment Research - Wed May 11, 8:01AM CDT
Repros' (RPRX) loss narrowed down from the year-ago period due to lower costs.
BSTC: 37.55 (+0.96), ARQL: 1.40 (-0.08), APRI: 0.34 (-0.01), RPRX: 2.00 (-0.03)

Jazz (JAZZ) Tops Q1 Earnings, Raises Earnings Outlook
Arpita Dutt - Zacks Investment Research - Wed May 11, 7:10AM CDT
Jazz (JAZZ) raised its earnings outlook for the year based on a lower share count.
BSTC: 37.55 (+0.96), JAZZ: 123.31 (-0.52), ARQL: 1.40 (-0.08), APRI: 0.34 (-0.01)

BioDelivery (BDSI) Posts In-Line Loss in Q1, Revenues Miss
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:49AM CDT
With Bunavail's sales trajectory not yielding desired results, BioDelivery (BDSI) is taking decisive actions to better align costs with revenue and reduce spending.
BDSI: 2.45 (+0.01), ENDP: 20.23 (-0.47), BSTC: 37.55 (+0.96), ARQL: 1.40 (-0.08)

ARIAD (ARIA) Q1 Loss Narrower But Revenues Disappoint (Revised)
Arpita Dutt - Zacks Investment Research - Wed May 11, 6:47AM CDT
ARIAD's (ARIA) decision to divest European operations should allow the company to focus on the U.S. market.
BSTC: 37.55 (+0.96), INCY: 80.81 (-0.29), ARQL: 1.40 (-0.08), ARIA: 10.19 (-0.15)

BioSpecifics Technologies Corp. Reports First Quarter 2016 Financial Results
PR Newswire - Tue May 10, 6:30AM CDT
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase based-therapies with a first in class collagenase-based product collagenase clostridium histolyticum, or CCH, marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the first quarter ended March 31, 2016 and provided a corporate update.
BSTC: 37.55 (+0.96)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Airswift's Strategic Acquisition Boosts U.S. Energy Presence

What's Driving Airswift's Latest Expansion? Airswift just dropped a bombshell by snapping up key businesses from New Tech Global (NTG), marking a serious power move in the U.S. energy sector. Now, what does this actually mean for investors? In blunt terms: they're muscling up their contractor base by a meaty 30%. That's no small feat. It's a calculated step to ace the...

Guaranteed Roof Expands with EM Exteriors through LB Capital

A Bold Move to Elevate Roofing Standards In a move that seems to jolt the roofing industry awake, Guaranteed Roof is taking the wraps off its new strategic partnership with LB Capital and EM Exteriors. Think of it as a power trio aiming to redefine what roofing solutions should mean in the Southeast. It’s the kind of news that makes you sit up and ask, why now and why...

Foodcare Proves Effective in Reducing Blood Sugar Levels

A New Chapter for Diabetes Care: Foodcare Folks, we've got ourselves a game-changer in the world of diabetes care. Listen closely: Foodsmart's latest study, hot off the press from the American Heart Association's Circulation, essentially hands over the blueprint for tackling type 2 diabetes in an innovative fashion. Now, I'm not the type to get all mushy over scientific...

Piedmont Orthopedics Expands Care in Henry County

A Surgeon's Story Comes to Henry County Ah, the medical field. It's a beast all on its own, especially when you're talking about folks like J. Hunter Matthews, M.D. making waves in the orthopedic world. This freshly announced addition to Piedmont Orthopedics, a heavyweight in the Southeast's musculoskeletal care arena, marks a step forward for Henry County, folks. We're...

Bud Ecosystem Debuts AIOS, Aims to Slash Costs

AI Fragmentation Tax: Cut It Out! Look, if you think AI is all about fancy algorithms and self-learning voodoo, you're missing the plot. It's the nuts and bolts—the infrastructure—that's been bleeding enterprises dry. That's where Bud Ecosystem comes thrashing in with its Novaria AIOS. They're not just promising a tiny tune-up; they're talking slashing AI costs by a...

Celebrating Appalachian Soul with Aristotle Jones

Igniting a Celebration of Appalachian Soul Now here's a sound that hits you right in the gut. Aristotle Jones, known out there as the 'Appalachian Soul Man,' is making a big move. He's laying out the plan to make July the Appalachian Soul Month. This fellow isn't shy about celebrating the deep roots of Appalachian music, dropping his album Appalachian Soul Power and a new...

Metriport Eyes Major Step in Health Data Integration

Metriport's Push into the TEFCA Framework Son of a gun, Metriport's making noise in the health data world! They just got the nod as a Candidate QHIN under the Trusted Exchange Framework and Common Agreement, or TEFCA if you're into acronyms. This isn't just some digital high-five; it's a significant stride forward for healthcare data exchange. Now they're smack in the...

WareSpace Expands Reach With $36.5M Acquisitions

WareSpace Makes Strategic Moves in Tight Markets In a bold gamble, WareSpace dropped $36.5 million to snag fresh industrial real estate in Miami Gardens, Florida, and South San Francisco, California. These aren't random picks, mind you. They're strategic grabs in markets where finding space ain't easier than winning the lottery. With more than 210 flexible units for small...

Andover Audio's FreePlay: Stereo Sound Goes Portable

If there's one thing I've seen grow in leaps and bounds, it's the audio world. Andover Audio’s latest move? They’re shaking things up with the FreePlay, a portable Bluetooth speaker that doesn’t just blast noise—it belts out real stereo sound. Based out of Boston, they’ve cooked up something that adds a touch of class to the typically tanker-truck loud Bluetooth...

Beetles Gel Polish Unveils Vibrant Fall Nail Carnival

Beetles Gel Polish Launches Fall Nail Carnival Here comes a new twist on fall fashion, and no, it ain’t your grandma's knitted sweater. We're talking nail polish—a vibrant, flashy ordeal brought to you by Beetles Gel Polish with their Fall Nail Carnival. They're rolling out this spectacle not just for your visions of grandeur nail ideas, but for those seeking deals...